足月儿产前暴露倍他米松的新生儿结局差异
该回顾性队列研究纳入5330名孕期诊断先兆早产并足月分娩的孕妇,其中1459名(27.5%)在平均孕32.2±3.3周接受倍他米松。校正母体特征和分娩孕周后,倍他米松暴露与新生儿重症监护室入院(aOR 1.49,95%CI 1.19-1.86)和小于胎龄儿(aOR 1.78,95%CI 1.48-2.14)风险升高相关,但与新生儿暂时性呼吸增快无显著关联。
要点
- 足月儿产前暴露倍他米松与NICU入院风险升高相关(aOR 1.49)。
- 倍他米松暴露与小于胎龄儿风险升高相关(aOR 1.78)。
- 倍他米松暴露与新生儿暂时性呼吸增快无显著关联(aOR 1.10)。
核心结论
- 与未接受倍他米松的先兆早产孕妇相比,接受倍他米松者所生足月儿NICU入院率和小于胎龄儿率更高。
- 倍他米松对早产儿的获益明确,但对足月分娩婴儿可能存在不良影响。
研究设计与样本
- 回顾性队列研究,纳入孕37周及以上分娩、孕期诊断先兆早产的婴儿。
- 共5330名孕妇,1459名(27.5%)接受倍他米松,平均给药孕周32.2±3.3周。
- 孕妇平均年龄27±5.9岁,平均分娩孕周38.9±1.1周。
主要发现
- 接受倍他米松的孕妇母体合并症(糖尿病、哮喘、高血压性疾病)发生率更高(P<.001),自我认同为白种人的比例更高(P=.022)。
- 倍他米松暴露新生儿的新生儿暂时性呼吸增快、NICU入院、小于胎龄儿、高胆红素血症和低血糖发生率均升高(均P<.05)。
- 校正母体特征和分娩孕周后,倍他米松暴露与新生儿暂时性呼吸增快无显著关联(aOR 1.10,95%CI 0.80-1.51)。
- 校正后,倍他米松暴露与NICU入院(aOR 1.49,95%CI 1.19-1.86)和小于胎龄儿(aOR 1.78,95%CI 1.48-2.14)风险升高相关。
临床怎么用
- 对先兆早产孕妇使用倍他米松时,应权衡早产获益与足月分娩时NICU入院和小于胎龄儿风险。
- 对接受过倍他米松但最终足月分娩的新生儿,需关注NICU入院和小于胎龄儿风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antenatal corticosteroids improve newborn outcomes for preterm infants. However, predicting which women presenting for threatened preterm labor will have preterm infants is inaccurate, and many women receive antenatal corticosteroids but then go on to deliver at term. OBJECTIVE: This study aimed to compare the short-term outcomes of infants born at term to women who received betamethasone for threatened preterm labor with infants who were not exposed to betamethasone in utero. STUDY DESIGN: We performed a retrospective cohort study of infants born at or after 37 weeks' gestational age to mothers diagnosed as having threatened preterm labor during pregnancy. The primary neonatal outcomes of interest included transient tachypnea of the newborn, neonatal intensive care unit admission, and small for gestational age and were evaluated for their association with betamethasone exposure while adjusting for covariates using multiple logistic regression. RESULTS: Of 5330 women, 1459 women (27.5%) received betamethasone at a mean gestational age of 32.2±3.3 weeks. The mean age of women was 27±5.9 years and the mean gestational age at delivery was 38.9±1.1 weeks. Women receiving betamethasone had higher rates of maternal comorbidities (P<.001 for diabetes mellitus, asthma, and hypertensive disorder) and were more likely to self-identify as White (P=.022). Betamethasone-exposed neonates had increased rates of transient tachypnea of the newborn, neonatal intensive care unit admission, small for gestational age, hyperbilirubinemia, and hypoglycemia (all, P<.05). Controlling for maternal characteristics and gestational age at delivery, betamethasone exposure was not associated with a diagnosis of transient tachypnea of the newborn (adjusted odds ratio, 1.10; 95% confidence interval, 0.80-1.51), although it was associated with more neonatal intensive care unit admissions (adjusted odds ratio, 1.49; 95% confidence interval, 1.19-1.86) and higher odds of the baby being small for gestational age (adjusted odds ratio, 1.78; 95% confidence interval, 1.48-2.14). CONCLUSION: Compared with women evaluated for preterm labor who did not receive betamethasone, women receiving betamethasone had infants with higher rates of neonatal intensive care unit admission and small for gestational age. Although the benefits of betamethasone to infants born preterm are clear, there may be negative impacts for infants delivered at term.
引用
- McKinzie AH, Yang Z, Teal E, et al. Are newborn outcomes different for term babies who were exposed to antenatal corticosteroids? Am J Obstet Gynecol. 2021. PMID: 33957112. doi:10.1016/j.ajog.2021.04.251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。